PPAR Research / 2008 / Article / Fig 8

Review Article

The Development of INT131 as a Selective PPAR 𝜸 Modulator: Approach to a Safer Insulin Sensitizer

Figure 8

INT131 does not increase plasma volume, heart weight, or lung weight. Zucker fatty rats were treated orally once daily for 14 days with 80 mg/kg/day of INT131 or rosiglitazone ( /group). (a) Hematocrit, (b) heart weight, and (c) lung weight were measured, and organ weights normalized to body weight. Adapted from [17, 19].